CARGO Therapeutics, Inc. is a biotechnology company focused on the development of innovative therapies for treating cancer and other serious diseases
The company specializes in harnessing and engineering cellular therapies, particularly in the field of immuno-oncology, to create targeted treatment options that aim to enhance the body’s natural ability to fight cancer. By leveraging advanced technologies and a deep understanding of the immune system, CARGO Therapeutics is committed to advancing groundbreaking treatments that can improve patient outcomes and provide new hope for those affected by difficult-to-treat conditions.
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
- Development of CRG-023 and allogeneic platform suspended; further reduction in force (RIF) of approximately 90% to preserve cash and maximize shareholder value -
Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session.
The DJS Law Group announces that it is investigating claims on behalf of investors of CARGO Therapeutics, Inc. (“CARGO” or “the Company”) (NASDAQ: CRGX) for violations of the securities laws.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CARGO Therapeutics, Inc. (“CARGO” or “the Company”) (NASDAQ: CRGX) for violations of the securities laws.
SAN CARLOS, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company advancing next generation, potentially curative cell therapies for cancer patients, today announced that it has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy. In-line with this decision, the Company will reduce its workforce to extend cash runway and prioritize the advancement of CRG-023 to Phase 1 proof-of-concept data as well as its novel allogeneic platform.
- 71 patients dosed in the potentially pivotal Phase 2 clinical study of firicabtagene autoleucel (firi-cel); Interim analysis results expected to be reported in 1H’25 -
SAN CARLOS, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next-generation, potentially curative cell therapies for cancer patients, today announced that the company will participate in the 43rd Annual J.P. Morgan Healthcare Conference, taking place January 13-16, 2025, in San Francisco, California.
- 57 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel); on track for interim analysis in 1H25 -
